# Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)

> **NCT00557622** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 5 (actual)

## Conditions studied

- Post-Traumatic Stress Disorder
- Stress Disorders, Post-Traumatic

## Interventions

- **DRUG:** paroxetine
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00557622
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01-25
- **Primary completion:** 2008-12-11
- **Final completion:** 2008-12-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** difficulty in achieving target enrollment numbers
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00557622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00557622, "Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00557622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*